Both the Kidney Disease Improving Global Outcomes guidelines and American Diabetes Association Standards of Care recommend GLP1-RA as the preferred glucose lowering class for people with T2D and moderate to advanced CKD or ESRD because of their demonstrated cardiovascular benefits in people with T2D at high risk of cardiovascular disease, which includes CKD13,14. This evidence concerns the gene GCG and diabetes mellitus.